TTNP: Titan Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TTNP: Titan Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 3.31
Enterprise Value ($M) 0.48
Book Value ($M) 2.44
Book Value / Share 2.67
Price / Book 1.36
NCAV ($M) 2.44
NCAV / Share 2.67
Price / NCAV 1.36

Profitability (mra)
Return on Invested Capital (ROIC) -1.93
Return on Assets (ROA) -0.71
Return on Equity (ROE) -0.77

Liquidity (mrq)
Quick Ratio 6.05
Current Ratio 6.05

Balance Sheet (mrq) ($M)
Current Assets 2.92
Assets 2.92
Liabilities 0.48
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -4.56
Net Income -4.71
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -3.88
Cash from Investing 0.00
Cash from Financing -0.06

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
08-21 13D/A Sire Group Ltd. 14.10 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2025-01-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. ☐ TRANSITION REPORT PURSUAN
2024-08-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. ☐ TRANSITION REPORT PURSUANT TO
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 140 392 35.71
2025-04-16 190 894 21.25
2025-04-15 785 2,214 35.46
2025-04-14 1,125 2,700 41.67

(click for more detail)

Similar Companies
TPST – Tempest Therapeutics, Inc. TRAW – Traws Pharma, Inc.
TSBX – Turnstone Biologics Corp. UNCY – Unicycive Therapeutics, Inc.
UPC – Universe Pharmaceuticals INC


Financial data and stock pages provided by
Fintel.io

Finpedia: Titan Pharmaceuticals